Article
BRAF mutations increase response to MEK inhibition
Lancet Oncology
Publication Date
12-1-2005
Document Type
Article
Disciplines
Abstract
Tumours with BRAF mutations, irrespective of site of origin, are sensitive to mitogen-activated protein kinase kinase (MEK) inhibitors, say researchers in Nature
Citation Information
Khabir Ahmed. "BRAF mutations increase response to MEK inhibition" Lancet Oncology Vol. 6 Iss. 12 (2005) p. 926 Available at: http://works.bepress.com/khabir_ahmed/8/